PO.ET03.03 · 实验与分子治疗

Novel Strategies to Reverse Drug Resistance

26 张海报 25 张含资料时间 Apr 22 2026 9:00AM 区域 Section 14

7112 · PDF 理解并克服三阴性乳腺癌脑转移对RET单药治疗的耐药性 Understanding and overcoming resistance of triple-negative breast cancer brain metastases to RET monotherapy Phi-Long Tran, Elissa Bloom, Angelina Regua, Shivani Bindal, Mariana Najja, Sham Syed, Hui-Wen Lo
7113 · PDF 通过FDA批准的口服活性、可穿透血脑屏障的RET与tGLI1抑制剂新型联合方案靶向治疗乳腺癌脑转移 Targeting breast cancer brain metastasis through novel combination of FDA-approved orally active BBB-permeable RET and tGLI1 inhibitors Joshua Cha, Angelina Regua, Mariana Najjar, Shivani Bindal, Elissa Bloom, Hui-Wen Lo
7114 · PDF BTK靶向降解剂在携带ibrutinib耐药突变的B细胞恶性肿瘤中的治疗潜力 Therapeutic potential of BTK targeted degrader in B-cell malignancies harboring ibrutinib-resistant mutation Shuai Zhao, Xiujuan Wu, Ting Ni, Jian Xiang, Zhixiang Zhang
7117 · PDF 药理学干扰YAP1/TEAD与NF-kappa B的相互作用可抑制前列腺癌 Pharmacological disruption of YAP1/TEAD and NF-kappa B crosstalk suppresses prostate cancer Sebnem Unlu, Abdulrahman M. Dwead, Marwah M. Al-Mathkour, Bekir Cinar
7118 · PDF TNKS抑制重塑AMOT-YAP信号以克服实体瘤中YAP驱动的治疗耐药 TNKS inhibition rewires AMOT-YAP signaling to overcome YAP-driven therapy resistance in solid tumors Jae Sung Kim, Young-Ju Kwon, Dong Young Kim, Yuna Kim
7119 · PDF 大规模药物筛选鉴定出克服边缘区淋巴瘤中BTK/PI3K抑制剂耐药的临床可操作联合方案 Large-scale drug screening identifies clinically actionable combinations to overcome BTK/PI3K inhibitor resistance in marginal zone lymphoma Alberto J. Arribas, Elena Mariotto, Eleonora Cannas, Giampietro Viola, Francesco Bertoni
7120 · PDF Rinzimetostat——一种用于治疗前列腺癌、具有同类最佳特性的变构EED抑制剂，在临床前研究中于PRC2甲基转移酶耐药情形下有效 Rinzimetostat, an allosteric EED inhibitor with best-in-class properties for the treatment of prostate cancer, is effective in PRC2 methyltransferase-resistant settings in preclinical studies Xi Chen, Livia Ulicna, Eunice Lopez-Fuentes, Anjana Ramnath, Ashley Pereira, Archana Kumar, Robert Warne, Kyle A. Edgar, Aleksandr Pankov, Jason E. Long, Ajit Narang, Lori S. Friedman, Anneleen Daemen, Melissa R. Junttila
7121 · PDF CRISPR可成药基因组筛选鉴定出BRD4作为在胰腺癌类器官中与天然产物cerberin协同的脆弱点 CRISPR druggable-genome screen identifies BRD4 as a synergistic vulnerability with the natural product cerberin in pancreatic cancer organoids Md Shahadat Hossan, Lauryn E. Flannagan, Michela Cadarso, Molly A. Nellen, Ethan S. Lin, Austin Stram, Dustin Rubinstein, Derek Pavelec, Mark E. Berres, Sean Ronnekleiv-Kelly, Jeremy D. Kratz
7122 · PDF 纳米颗粒介导的多发性骨髓瘤中pomalidomide敏感性的恢复 Nanoparticle-mediated restoration of pomalidomide sensitivity in multiple myeloma Joseph Uche Ogbede, Kaiqi Long, Michael S. Rogers, Jinjun Shi, Robert J. D'Amato, Bruce R. Zetter
7123 · PDF QW-5-70靶向秋水仙碱位点以克服多药耐药并表现出强效抗肿瘤活性 QW-5-70 targets the colchicine site to overcome multidrug resistance and shows potent antitumor activities Yang Xie, Ruida Hou, Najah Albadari, Hao Chen, Darcie J. Miller, Judith Quadrozzi Gruntz, Michael L. Oldham, Mir Shahriar Kamal, Jianxiong Jiang, Zhongzhi Wu, Duane D. Miller, Wei Li
7124 · PDF 胆管癌对SFK抑制剂NXP900的耐药以IL13RA2-AKT信号为特征，可通过联合治疗加以克服 Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy Shelby K. Yee, Hendrien Kuipers, Danielle M. Carlson, Jack W. Sample, Enis Ozmert, Hidemi Nishi, Erik Jessen, Dong-Gi Mun, Aushinie M. Abeynayake, Jennifer L. Tomlinson, Amro M. Abdelrahman, Nathan W. Werneburg, Binbin Li, Mitesh J. Borad, Mark J. Truty, Sumera I. Ilyas, Gregory J. Gores, Rory L. Smoot
7125 · PDF HDAC6抑制剂耐药的机制基础揭示蛋白酶体抑制是乳腺癌中一种合理的联合策略 Mechanistic basis of resistance to HDAC6 inhibitors reveals proteasome inhibition as a rational combination strategy in breast cancer Jose Silva, Tizita Zewde Zeleke, Qingfei Pan, Jiyang Yu
7126 · PDF 靶向Aurora A激酶联合替代性存活信号可克服ER+乳腺癌对内分泌治疗和CDK4/6治疗的耐药 Targeting Aurora A kinase together with alternative survival signaling overcomes resistance to endocrine and CDK4/6 therapies in ER+ breast cancer Chia-Chia Liu, Alekya Raghavan, Lanfang Qin, Sarmistha Nanda, Fu-Tien Liao, Georg F. Bischof, Mothaffar F. Rimawi, C. Kent Osborne, Jamunarani Veeraraghavan, Rachel Schiff
7127 · PDF RalBP1抑制：前列腺癌的一种新型疗法 RalBP1 inhibition: A novel therapy for prostate cancer Sharad S. Singhal, Madhu Krishna, Prakash Kulkarni, David Horne, Ravi Salgia
7128 · PDF YAP的崛起：胶质母细胞瘤治疗的新希望 The rise of YAP: A new hope in glioblastoma treatment Shuhan Cao, Ethan C. L. Wong, Gilberto K. K. Leung, Karrie M. Y. Kiang
7129 7129 在晚期前列腺癌中用临床阶段ATM抑制剂靶向PARPi药物耐受持续性及治疗中进展 Targeting PARPi drug tolerant persistence and progression on treatment with clinical stage ATM inhibitors in advanced prostate cancer Akshaya Karthikeyan, Bryan Correa Gonzalez, Jose G. Torres-Gonzalez, Love A. Moore, Anamitra Bhaumik, Ethan Sandoval, Alan P. Lombard
7130 · PDF GRN-300通过抑制HDAC-MEF2A-RAD51通路在BRCA2回复突变卵巢癌中恢复PARP抑制剂敏感性 GRN-300 restores PARP inhibitor sensitivity through inhibition of the HDAC-MEF2A-RAD51 pathway in BRCA2-revertant ovarian cancer Carlos Flores Suarez, Janice M. Santiago-O'Farrill, Weiqun Mao, Hailing Yang, Zhen Lu, Robert C. Bast
7131 · PDF 靶向氧化磷酸化的lixumistat可克服卵巢癌中的PARP抑制剂耐药 Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer Sa deok Hong, Min Sil Kang, Nar Katuwal, Mithun Ghosh, Seong Min Park, Kim Ju Hyeon, Seul-Gi Kim, Yong Wha Moon
7132 · PDF Rinzimetostat阻断PRC2活性——一种关键的治疗耐药机制——可改善多种前列腺癌模型对雄激素受体通路抑制的应答 Rinzimetostat blockade of PRC2 activity, a key mechanism of treatment resistance, improves response of androgen receptor pathway inhibition across a spectrum of prostate cancer models Aleksandr Pankov, Amber W. Wang, Natalie Yuen, Livia Ulicna, Jason E. Long, Xi Chen, Gina Andretta, Lori S. Friedman, Melissa R. Junttila, Anneleen Daemen
7133 · PDF 抗CSF-1R与抗TIM-3联合可克服BRCA1相关三阴性乳腺癌中巨噬细胞介导的PARP抑制剂(PARPi)耐药机制 Combined anti-CSF-1R and anti-TIM-3 overcome macrophage-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer Adam Nelson, Anita K. Mehta, Madeline G. Townsend, Daniel E. Michaud, Madisson Oliwa, Kelly F. Zheng, Carlos W. S. Wanderley, Alex P. Gottlieb, Kenichi Shimada, Patrice A. Lee, Nicholas A. Saccomano, Filipa Lynce, Nabihah Tayob, Geoffrey I. Shapiro, Jennifer L. Guerriero
7134 · PDF 利用MTAP缺失非小细胞肺癌和间皮瘤的患者来源异种移植模型，开发与新型MTA协同性PRMT5抑制剂AMG 193的药物联合方案 Developing drug combinations with AMG 193, a novel MTA-cooperative PRMT5 inhibitor, using patient-derived xenograft models of MTAP -deleted non-small cell lung cancer and mesothelioma Florence T. H. Wu, Nhu-An Pham, Yu-Hui Wang, Ming Li, Nikolina Radulovich, Katrina Hueniken, Quan Li, Siyuan (Claret) Liu, Brian Belmontes, Paul Hughes, Ming-Sound Tsao, Adrian Sacher
7135 · PDF 一种首创的口服生物利用度小分子，用于克服激素受体阳性乳腺癌的治疗耐药 A first-in-class orally bioavailable small molecule to overcome treatment resistance in hormone receptor-positive breast cancer Hee-Sung Park, Chakrapani Subramanyam, Kyu-kwang Cho, Se Hee Hyun, Yeonjee Kahm
7137 · PDF 靶向RRM2以增强TNBC对PARP抑制剂的敏感性 Targeting RRM2 to enhance PARP inhibitor sensitivity in TNBC Tamanna Islam, Howard L. Elford, Jesika S. Faridi
7138 · PDF BRCA1缺陷三阴性乳腺癌中获得性saruparib (AZD5305)耐药对DNA损伤应答靶向疗法敏感 Acquired saruparib (AZD5305) resistance in BRCA1-deficient triple negative breast cancer is vulnerable to DNA damage response-targeted therapeutics Matthew R. Jordan, Pamela S. VanderVere-Carozza, Jessica Lynn Kersey, Katherine Pawelczak, John J. Turchi
7139 · PDF 揭示PGRMC1-PARP相互作用：三阴性乳腺癌中一种新型联合治疗策略 Uncovering PGRMC1-PARP interaction: A novel combination therapeutic strategy in triple-negative breast cancer Mahalakshmi Vijayaraghavan, Ramadevi Subramani, Michel Rojo Amador, Kyle Nguyen, Kariina Garcia, Poornima Devi Narayanan, Alfredo Roman, Abigail Ramirez, Jazmin Lopez, Rajkumar Lakshmanaswamy
7140 · PDF Hsp90beta选择性抑制与PARPi在同源重组修复功能正常的卵巢癌中的合成致死作用 Synthetic lethality of Hsp90beta-selective inhibition with PARPi in homologous recombination repair proficient ovarian cancer Sanket Mishra

在会议检索中浏览本分会场